Additional prognostic value of polymorphisms within the 3'-untranslated region of programmed cell death pathway genes in early-stage breast cancer
View abstract on PubMed
Summary
This summary is machine-generated.Genetic variants in programmed cell death pathway genes are linked to breast cancer survival. Four specific SNPs (rs4900321, rs7150025, rs6753785, rs2213181) may serve as biomarkers for early-stage breast cancer outcomes.
Area Of Science
- Oncology
- Genetics
- Molecular Biology
Background
- Programmed cell death (PCD) pathway is crucial for cancer control.
- Limited research exists on genetic variants in PCD pathway 3'-untranslated regions and breast cancer prognosis.
Purpose Of The Study
- To investigate the association between genetic variants in PCD pathway genes and early-stage breast cancer (EBC) outcomes.
- To identify potential genetic biomarkers for predicting EBC survival.
Main Methods
- Genotyped 28 single nucleotide polymorphisms (SNPs) in 23 PCD pathway genes in 1,177 early-stage breast cancer patients.
- Median follow-up of 174 months.
- Analyzed associations with invasive disease-free survival (iDFS), distant disease-free survival (DDFS), breast cancer-specific survival (BCSS), and overall survival (OS).
Main Results
- Four independent SNPs (rs4900321, rs7150025 in ATG2B; rs6753785 in BCL2L11; rs2213181 in c-Kit) were significantly associated with survival outcomes.
- Combined genotypes of these SNPs showed a dose-dependent decrease in survival with increasing unfavorable genotypes (Ptrend < 1.0 × 10-6).
- Combined genotypes improved prediction of EBC survival when integrated with clinicopathological variables (P < 0.05).
- Two SNPs (rs6753785, rs2213181) correlated with BCL2L11 and c-Kit mRNA expression, respectively.
Conclusions
- The identified four SNPs may serve as novel biomarkers for predicting early-stage breast cancer survival.
- These SNPs potentially influence survival by modulating the expression of corresponding PCD pathway genes.

